Biennial mammography optimal screening interval for average risk women
the ONA take:
A comprehensive analysis of digital mammography tests has indicated that biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
This screening frequency should offer a good balance between prudent detection and the risk of false-positive results.
The study findings indicated that biennial screening maintains an average of 81.2% of annual screening benefits with fewer false-positives; whereas annual screening, although it could avert 3 more cancer deaths, would yield approximately 1988 additional false-positive test results.
This study was a collaboration between six modeling research groups that belong to CISNET, the NCI-sponsored Cancer Intervention and Surveillance Modeling Network, coupled with investigators based at the Breast Cancer Surveillance Consortium (BCSC).
The paper's lead author was Jeanne S. Mandelblatt, MD, MPH, of Georgetown Lombardi Comprehensive Cancer Center (CISNET).
The modeling incorporated national data on breast cancer risk, treatment effects, and incidence of breast cancer; and reviewed one- and two-year screening intervals on individuals with varying starting ages. The research also considered digital screening and breast density factors.
Other modeling findings revealed that biennial screening during the age span of 50-74 would achieve a roughly 25% mortality reduction. Starting the biennial screening at age 40 averts an average of one additional cancer death but also generates an average of 576 additional false-positive tests.
The paper's lead author cautioned that these model findings should still not override a screening frequency determination based on individual factors, based on acceptance of false-positive results, over treatment, etc. She stated that screening frequency must be balanced against the risk of chemotherapy and/or radiation treatment that may not needed.
Biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including Informal Caregivers of Elderly in Discharge Process Reduces Readmission Risk
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|